06.06.2013 Celesio AG  DE000CLS1001

DGAP-News: Celesio AG: The Celesio management board is complete again: Martin Fisher appointed COO


 
DGAP-News: Celesio AG / Key word(s): Change of Personnel Celesio AG: The Celesio management board is complete again: Martin Fisher appointed COO 06.06.2013 / 15:15 --------------------------------------------------------------------- The Celesio management board is complete again: Martin Fisher appointed COO Stuttgart, 6 June 2013. The Celesio AG supervisory board has appointed Martin Fisher (53) to the management board, which he will join by 1st October 2013 the latest. In his most recent role Fisher was Head of Global Supply Chain at Arysta Lifescience. Fisher will run Celesio's Operations divisions comprising the group-wide responsibility for procurement, supply chain management, quality management and regulations, as well as IT. Celesio CEO Markus Pinger: 'We are very happy that Martin Fisher will complete the Celesio management board. Martin Fisher has many years of international experience in global supply chain management. The further development of our logistics, procurement and IT activities is a vital success factor in the integration of our retail and wholesale activities and the creation of a completely integrated end-to-end business model. This is the core of our strategic realignment.' After completing his degree in the UK, British-born Martin Fisher worked at several international companies such as Benckiser and Coty in leading positions in the area of operations/supply chain/logistics. Prior to joining Dairy Crest Group PLC in 2007 in the function of Group Operations Director, he was Senior Vice President Supply, Developing Markets at Reckitt Benckiser PLC from 2000. In 2009, Martin Fisher was appointed Global Head, Supply Chain at Arysta. Press contact Dr Jens Schreiber, Celesio AG, +49 (0)711.5001-380 [email protected] Rainer Berghausen, Celesio AG, +49 (0)711.5001-549 [email protected] About Celesio Group As a leading international trading company and provider of logistics and services in the pharmaceutical and healthcare sector, Celesio takes a proactive and preventive approach to ensuring that patients receive the products and support that they require for optimum care. With 39,000 employees, we operate in 16 countries around the world. Every day, we serve over 2 million customers - at 2,200 pharmacies of our own and 4,100 participants in our brand partnership schemes. With around 140 wholesale branches, we supply approximately 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. Our services benefit a patient pool of about 15 million per day. End of Corporate News --------------------------------------------------------------------- 06.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Germany Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-740 E-mail: [email protected] Internet: www.celesio.com ISIN: DE000CLS1001 WKN: CLS100 Indices: MDAX Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime Standard), München, Stuttgart; Freiverkehr in Hamburg, Hannover; Terminbörse EUREX End of News DGAP News-Service --------------------------------------------------------------------- 215261 06.06.2013


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 21.090,00 20.643,70 21.090,00 16.416,80 8.517,70 9.257,10 0,00
EBITDA1,2 147,50 393,90 147,50 137,10 126,30 113,50 0,00
EBITDA-Marge3 0,70 1,91 0,70 0,84 1,48 1,23 0,00
EBIT1,4 -284,60 -699,40 -284,60 2,70 -12,50 -46,30 0,00
EBIT-Marge5 -1,35 -3,39 -1,35 0,02 -0,15 -0,50 0,00
Jahresüberschuss1 -299,00 -966,00 -295,30 -54,60 -7,30 -867,40 0,00
Netto-Marge6 -1,42 -4,68 -1,40 -0,33 -0,09 -9,37 0,00
Cashflow1,7 265,90 422,30 265,90 345,00 362,50 0,90 0,00
Ergebnis je Aktie8 -1,49 -3,97 -1,47 -0,29 -1,22 -4,29 0,64
Dividende8 0,83 0,83 0,83 0,83 0,83 0,83 0,83
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
McKesson Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
CLS100 20,900 Halten 4.247,32
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
26,13 22,44 1,15 -24,62
KBV KCV KUV EV/EBITDA
1,70 4.719,24 0,46 21,30
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,83 0,83 3,97 29.07.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.06.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,68% -3,58% -12,92% -12,92%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Celesio AG  ISIN: DE000CLS1001 können Sie bei EQS abrufen


Handel , CLS100 , CLS1 , SWB:​MCK